Development of a PBPK Model for Docetaxel as a CYP3A Substrate and Accounting for Binding to Multiple Plasma Proteins
0 comments.
Click here to read/write comments.
Topics:
Authors: Iain Gardner
Certara’s Best of the Blog 2017
A selection of short essays from our blog, written to empower our customers with modeling and simulation (M&S) and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing and sharing clinical trial results.
Read More
0 comments.
Click here to read/write comments.
Topics:
Physiologically-based Pharmacokinetic (PBPK) Modeling to Explore the Potential Role of Cytochrome P450 3A Enzyme in Colonic Drug Metabolism—Oxybutynin: A Case Study
0 comments.
Click here to read/write comments.
Topics:
Use of a PBPK Modeling Approach to Predict the In Vivo Clearance of Aldehyde Oxidase Substrates
0 comments.
Click here to read/write comments.
Topics:
Evaluation of In Vitro-In Vivo Extrapolation (IVIVE) of the Induction Potential for Known CYP 2C9 Inducers
0 comments.
Click here to read/write comments.
Topics:
Abundance & Relative Segmental Expression of Intestinal Transporters in Caucasians: A Meta-analysis
0 comments.
Click here to read/write comments.
Topics:
In Vitro-In Vivo Extrapolation of Intestinal Transporter Activity Using an Absolute Transporter Abundance Approach Within a PBPK Framework
0 comments.
Click here to read/write comments.
Topics:
Version Comparison and Performance Verification of Library Compounds Within the Simcyp Simulator
0 comments.
Click here to read/write comments.
Topics:
Performance Verification of v17 Sim-cancer Population in Simcyp
0 comments.
Click here to read/write comments.
Topics:
Evaluation of In Vitro-In Vivo Extrapolation (IVIVE) of the Induction Potential for Known CYP2C9 Inducers
0 comments.
Click here to read/write comments.
Topics:
A Whole Body Physiologically-based Pharmacokinetic Model for Antibody Drug Conjugates—Model Development and Validation in Rat
0 comments.
Click here to read/write comments.
Topics:
New Tools Support Developing Better TB Drugs
Tuberculosis (TB)—caused by infection with the mycobacterium Mycobacterium tuberculosis—is one of the top 10 leading causes of death worldwide with a total of 1.8 million people dying from the disease in 2015. TB is also the leading cause of death in HIV-infected individuals. TB usually attacks the lungs but can infect any part of the […]
Read More
0 comments.
Click here to read/write comments.
Topics:
PBPK Modeling & SimulationExtension of Simcyp Brain Model for Proteins to Investigate Transferrin Receptor Transport
0 comments.
Click here to read/write comments.
Topics:
Prediction of Large Molecule Clearance in Children Using Allometry vs. PBPK—Erythropoietin as a Case Example
0 comments.
Click here to read/write comments.
Topics:
Extension of Simcyp Brain Model for Proteins to Investigate Transferrin Receptor Transport
0 comments.
Click here to read/write comments.
Topics:
A Multi-compartment Liver Model for the Prediction of Toxicokinetics
0 comments.
Click here to read/write comments.
Topics:
PBPK Modeling of Target Organ Concentrations for Reverse Dosimetry
0 comments.
Click here to read/write comments.
Topics:
Certara’s Best of Blogs 2015
A selection of short essays from our blog, written to empower our customers with biosimulation and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing.
Read More
0 comments.
Click here to read/write comments.
Topics:
A Novel Mechanistic Approach to Predict the Steady State Volume of Distribution (Vss) Using the Fick-Nernst-Placnk Equation
0 comments.
Click here to read/write comments.
Topics:
Development of a Novel Multi-compartment Granuloma Model to Predict Local Drug Distribution and Its Impact on Pharmacodynamics and Disease Progression in Tuberculosis
Objectives: One of the hallmarks of pulmonary tuberculosis (TB) is the formation of granulomas, heterogeneous lesions composed of macrophage and neutrophil rich peripheral regions and a necrotic core, in the lungs of the infected host. Anti-TB drugs must penetrate these lesions to exert their effects. This work aimed to extend a permeability-limited lung model [1] […]
Read More
0 comments.
Click here to read/write comments.
Topics: